ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,977Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 224

$492K Total Retail Price of All Prescriptions

Rank: 11 out of 224

395 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
66% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 395 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

9% of this provider’s 395 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,202 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
METOPROLOL TARTRATE 335 291 1 7
LEVOTHYROXINE SODIUM 289 241 2 4
FUROSEMIDE 288 272 3 5
OMEPRAZOLE 275 218 4 3
SIMVASTATIN 264 226 5 1
LISINOPRIL 260 219 6 2
HYDROCHLOROTHIAZIDE 247 228 7 6
LOVASTATIN 241 182 8 33
METOPROLOL SUCCINATE 210 192 9 11
WARFARIN SODIUM 204 161 10 10
SERTRALINE HCL 189 174 11 17
AMLODIPINE BESYLATE 153 129 12 8
ATENOLOL 150 139 13 13
HYDROCODONE-ACETAMINOPHEN 147 92 S3 14 12
PANTOPRAZOLE SODIUM 144 119 15 27
TRAZODONE HCL 131 98 16 20
METFORMIN HCL 131 108 16 9
RANITIDINE HCL 118 98 18 29
DONEPEZIL HCL 112 105 19 36
POTASSIUM CHLORIDE 104 103 20 24
FLUOXETINE HCL 98 81 21 37
RISPERIDONE 84 74 22 50
MORPHINE SULFATE ER 84 26 S2 22 47
GABAPENTIN 77 41 24 14
ISOSORBIDE MONONITRATE ER 76 68 25 70
CITALOPRAM HBR 75 61 26 15
KLOR-CON M20 73 61 27 81
METHADONE HCL 72 12 S2 28 53
ALLOPURINOL 70 68 29 40
CARBIDOPA-LEVODOPA 69 59 30 80
TRAMADOL HCL 67 54 31 18
NEXIUM 67 52 31 34
QUETIAPINE FUMARATE 67 60 31 55
NAMENDA 66 66 34 65
ALENDRONATE SODIUM 65 57 35 39
MIRTAZAPINE 64 60 36 54
MORPHINE SULFATE 64 0 S2 36 112
GLIPIZIDE 61 52 38 69
ZOLPIDEM TARTRATE 60 28 39 22
TAMSULOSIN HCL 59 51 40 30
SUBOXONE 57 0 41 31
ACETAMINOPHEN-CODEINE 55 51 S3 42 129
SPIRIVA 55 49 42 32
LANTUS 53 48 44 43
ADVAIR DISKUS 52 51 45 23
PREDNISONE 51 37 46 28
SPIRONOLACTONE 51 49 46 67
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 28, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.